AC Immune
Update in progressACIU (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
AC Immune SA is a clinical‑stage biopharmaceutical company focused on neurodegenerative diseases linked to protein misfolding. Using SupraAntigen and Morphomer platforms, it develops biologics and small molecules that selectively target misfolded proteins. Its programs include Crenezumab and Semorinemab for Alzheimer's, ACI‑24.060 for Down syndrome–AD, and ACI‑7104.056 for Parkinson's, plus Tau imaging and diagnostic tools. It collaborates with Genentech, Janssen, Life Molecular Imaging and Eli Lilly and is based in Lausanne, Switzerland.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.05
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!